Login
Jade Biosciences, Inc. logo

Jade Biosciences, Inc.

jadebiosciences.com

What Do They Do?

Develops antibody medicines for people with autoimmune diseases, including candidates for IgA nephropathy, rheumatoid arthritis and dermatomyositis.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −39% (Loss)
vs −$25.2M in Q3 FY2025
  • Nov 13, 2026 JADE101 Phase 3 trial expected to start in fourth quarter of 2026 The company also reported ongoing Phase 2 and Phase 1 trials for JADE101 and JADE201, respectively.
  • Jun 29, 2026 Jade secured an exclusive license for JADE301 Paragon granted a worldwide license to develop, make and sell products against the target, with milestone payments and royalties tied to product sales.

From PAH to autoimmune diseases The older report described Aerovate’s focus as developing an inhaled drug for pulmonary arterial hypertension. The latest report describes Jade as developing antibody therapies for autoimmune diseases.

Who Do They Compete With?

Competes with Otsuka, Novartis, Vera Therapeutics, Vertex, and Climb Bio

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support